In the present study we investigated the life-cycle, trafficking, assembly and cell surface dynamics of a poorly characterized connexin family member, connexin 30 (Cx30), which plays a critical role in skin health and hearing. Unexpectedly, Cx30 localization at the cell surface and gap junctional intercellular communication was not affected by prolonged treatments with
INTRODUCTION
Gap junctions are intercellular channels that permit the direct transfer of ions and small molecules (<1-1.5 kDa in size) between adjacent cells, in a process termed gap junctional intercellular communication (GJIC) (Alexander and Goldberg, 2003) . Each gap junction channel, composed of two inter-docked hexameric connexons provided by apposing cells, can be composed of single (homotypic) or mixed (heterotypic) connexin family members. Under specific physiological conditions un-docked connexons at the cell surface can also function as hemichannels that exchange small molecules between the intra-and extra-cellular environments (Evans et al., 2006) . Given that 21 connexin subtypes exist in humans and that most cell types express more than one connexin at any one time, a huge variety of gap junction and hemichannel configurations are possible (Laird, 2006) . This complexity is evident in the skin epidermis where up to ten different connexins are expressed at various stages of the keratinocyte life cycle (Martin et al., 2014) . This suggests that each channel type will exhibit some unique features and functions. Connexin 30 (Cx30) is specifically expressed in skin keratinocytes (Di et al., 2001 ), brain astrocytes (Dahl et al., 1996) retinal astrocytes (Mansour et al., 2013) and various inner ear cell types (Forge et al., 2003a) . Mutations in the Cx30-encoding gene GJB6 cause skin disease or hearing loss, or a combination of both (Xu and Nicholson, 2013) suggesting an essential role for Cx30 in these systems.
The connexin life-cycle is a dynamic process that leads to the efficient and quick turnover of gap junction plaques at the cell surface, usually within 1.5-5 hours (Beardslee et al., 1998; Laing et al., 1997; Laird et al., 1995; Laird et al., 1991) . Other than Cx46, which has been shown to have a slow turnover rate in enucleated lens fibre cells (Jiang et al., 1993) , connexins with short C-terminal tails, such as Cx26 and Cx30, are regulated in the absence of protein interacting sites. To date, very few studies have investigated the life-cycle of Cx30.
In contrast to Cx43, some reports have suggested variations in the life-cycle of Cx26, and more recently Cx30. First, Cx26 has been suggested to post-translationally insert into ER membranes in cell-free in vitro systems (Ahmad et al., 1999; Zhang et al., 1996) and even directly into plasma membranes (Ahmad and Evans, 2002) . However, these findings have not been found in vivo. Second, based on their insensitivity to the ER-Golgi transport blocker brefeldin-A (BFA) both Cx26 and Cx30 have been suggested to traffic to the cell surface via Golgi-independent pathways (George et al., 1999; Martin et al., 2001; Qu et al., 2009 ). In contrast, data from our laboratory has since shown that Cx26 follows a similar trafficking pathway through the Golgi apparatus similarly to Cx43 (Thomas et al., 2005) . Third, the dependence on intact microtubules for correct trafficking to the cell surface is essential for Cx43 -which contains binding sites for both tubulin and ZO-1 (Giepmans et al., 2001a; Giepmans et al., 2001b) , but is not necessary for Cx26 targeting in NRK cells and BICR-M1Rk mammary tumor cells (Thomas et al., 2001; Thomas et al., 2005) or Cx30 in HeLa cells (Qu et al., 2009 ). In the latter study, Cx30 was shown to interact with actin and β-tubulin, but not the tight junction protein ZO-1, suggesting a novel role for actin based trafficking/stabilization of Cx30 gap junctions (Qu et al. 2009 ).
In this study we have investigated various aspects of the Cx30 life-cycle with particular focus on the trafficking and stability of Cx30 at the cell surface. In contrast to what has been reported for Cx26 previously (George et al., 1999; Martin et al., 2001 ) and has more recently been suggested for Cx30 (Qu et al., 2009) , we found that Cx30 traffics via the classical secretory pathway through the Golgi apparatus before reaching the cell surface. In comparison to the short 1-5 hour half-lives determined for Cx26, Cx32, Cx43 and Cx45 (Beardslee et al., 1998; Darrow et al., 1995; Fallon and Goodenough, 1981; Laing et al., 1997; Laird et al., 1995; Laird et al., 1991; Thomas et al., 2005; Traub et al., 1989) , we found that Cx30 has an unusually long half-life at the cell surface. In order to facilitate differential clearing of Cx30 and Cx43 from the cell surface we found that these connexins were segregated into distinct regions within the same gap junction plaque. In addition, disrupting the actin and microtubule cytoskeletal networks did not adversely affect the stable nature of Cx30 plaques at the cell surface, whereas those formed of Cx43 became less organized and internalized. These features suggest that connexin turnover and life cycles vary markedly between Cx30 and Cx43.
RESULTS

Cx30-GFP dynamics in living cells
To study Cx30 dynamics in living cells (without the influence of other connexins) Cx30-GFP was expressed in HeLa cells and its movement, remodelling and clearing form the cell surface was assessed. HeLa cells were efficient in assembling Cx30 gap junction plaques at the cell-cell interfaces (Fig. 1) . To assist in determining the dynamic properties of Cx30-GFP gap junctions, we photobleached three clearly defined plaques (Fig.1 , circles labelled 1, 2 and 3) and assessed their recovery over time. Within the 2 hr 20 min recording period, the photo-bleached plaques were relatively slow to recover and did not fully reach pre-bleach levels; however, GFP fluorescence was visible within the bleached areas (1 and 3) indicating partial plaque replenishment. Note, the bleached plaque in region 2 did not recover due to separation of the cells. Non-bleached plaques were either very stable or were wholly internalised into a single cell in structures similar in appearance to connexosomes, as has been reported for other connexins (Jordan et al., 2001; Jordan et al., 1999; Piehl et al., 2007) .
Interestingly, connexosomes were either degraded rapidly and disappeared or hovered near the cell surface (see arrows, Fig. 1 and Supplemental Movie 1).
Cx30-GFP gap junction plaques are replenished at the outer edge
To further investigate Cx30 dynamics and gap junction plaque replenishment, Cx30-GFP plaques between HeLa cells were photobleached (red box, Fig. 2 ) and fluorescence recovery after photobleaching (FRAP) recorded over a 2 hr period (Fig. 2) . Composite images of Cx30-GFP fluorescence (green) and DIC were taken from a z-stack plane at the time points indicated in the upper panel of Fig. 2 . Z-stacks were also processed into 3D reconstructions for further in-depth FRAP analysis and rotated so that the plaque region was almost en face leads to an accumulation of Cx43 in the ER and, due to its fast turnover rate, loss of Cx43 plaques at the cell surface within 6 hrs (Laird et al., 1995; Martin et al., 2001; Thomas et al., 2005) . We investigated whether Cx30 exhibits similar kinetics in HeLa cells in comparison to Cx26 and Cx43. Cx30 gap junction plaque numbers were not noticeably reduced in the presence of BFA, whereas Cx26 localization was more perinuclear and Cx43 exhibited a profile resembling the location of the ER (Fig. 3A) . Continuous introduction of neurobiotin into a single cell via whole-cell patch clamp and subsequent streptavidin detection of neurobiotin spread after 10 minutes revealed that BFA greatly reduced coupling in Cx43 and Cx26 expressing cells (P<0.001) but not Cx30 expressing cells (P=0.656, Fig. 3B ). The resistance of Cx30 gap junctions to clearing from the cell surface in the presence of BFA, even after prolonged treatments of 18 hrs, was further confirmed in Cx30 expressing keratinocytes (REKs) (Fig. 4A) and NRKs (Fig. 4B) . In many REKs, Cx30 accumulated in the ER, as determined by co-localization with the ER marker PDI (green, inset), but still retained gap junction plaques (arrows, Fig. 4A ). This indicates that when ER-to-Golgi transport is blocked, Cx30 is unable to exit the ER along the classical secretory pathway.
Cx30 trafficking to the cell surface is inhibited by a Sar1 dominant-negative mutant
Although Cx30 plaques were persistent at the cell surface in the presence of BFA, we could not rule-out the possibility of a direct Golgi-independent trafficking pathway playing a role in replenishing the gap junction plaques, as has been previously suggested (Qu et al., 2009) . To address this possibility we co-expressed Cx43 or Cx30 together with a DsRed2-tagged dominant-negative mutant (H79G) form of Sar1 (Secretion-associated RAS-related protein 1) to prevent protein transport to the cis-Golgi, as we have reported previously (Thomas et al. 2005; Bhalla-Gehi et al 2010) (Fig. 5A, B) . Wild-type Sar1 was localized to perinuclear regions where its expression had no effect on Cx43 gap junction plaque formation (Fig. 5A ).
Upon Sar1
H79G expression Cx43 exhibited an ER-like pattern and appeared to lose gap junction plaques at the cell surface (Fig. 5A) . In a similar fashion, REKs co-expressing Cx30 and wildtype Sar1 had no discrepancies in their ability to form gap junction plaques, whereas Sar1 H79G caused Cx30 to be retained in an ER-like pattern and led to a loss of gap junction plaques between cells (Fig. 5B) . These results suggest that Cx30 is transported through the Golgi apparatus.
Cx30 protein has an extended half-life compared to Cx43 in keratinocytes
To assess the relative half-life of Cx30, REKs that co-expressed Cx30 and Cx43 were treated with the translational inhibitor cycloheximide (CHX) for up to 8 hrs and connexin content evaluated by immunofluorescent labelling and Western blots (Fig. 6A, B ). While Cx43 levels were quickly reduced (Fig. 6A, B ), Cx30 levels remained relatively unchanged for up to 8 hr of CHX treatment suggesting that Cx30 has a prolonged half-life compared to Cx43.
To further assess the prolonged half-life for Cx30, REKs co-expressing Cx43 and Cx30
were treated with BFA for 7 hrs before separating the cell lysate into Triton soluble (non-plaque pool) or Triton insoluble (plaque pool) fractions. In control cells, immunoblot analysis revealed similar levels of total Cx43 in both the soluble and insoluble fractions ( The ratio of insoluble protein after BFA treatment to control insoluble protein revealed a significant reduction of the total (P<0.001) and phosphorylated (P<0.001) Cx43 species in comparison to Cx30 (Fig. 7E ). These results further suggest that Cx30 exhibits an extended half-life projected to be > 12 hrs (estimated from the average reduction in intensity over 8 hours, to the point where the intensity would be predicted to have dropped by 50% from the starting value) when assembled into gap junction plaques.
Disruption of cytoskeletal elements does not destabilize Cx30 gap junctions
To determine the effect of disrupting cytoskeletal elements on Cx30 containing gap junction plaques at the cell surface, REKs expressing Cx30 and Cx43 were treated with cytochalasin B (cytoB) to disrupt actin microfilaments (supplementary material Fig. S1 ) or nocodazole to depolymerize microtubules (supplementary material Fig. S2 ). Treatment with cytoB initiated a reduction in filamentous actin and led to a reduction in cortical actin staining at the cell border; however there was no discernible change in Cx30 gap junction plaques even after 10 hrs of treatment (supplementary material Fig. S1 ). In contrast, Cx43 puncta at cell-cell interfaces (0 hr) appeared reduced after 2 hours of cytoB treatment and Cx43 localization was more intracellular. This suggests that actin filaments do not play a role in stabilizing Cx30 gap junctions. Treatment with nocodazole completely depolymerized microtubules within 2 hrs as assessed by β-tubulin staining (supplementary material Fig. S2 ). This had no detrimental effect on Cx30 gap junctions even after 10 hrs of treatment while many cell surface Cx43 plaques were lost after only 2 hours of treatment.
Cx30 and Cx43 segregate and partition into distinct regional domains within the same gap junction plaques
Since Cx30 and Cx43 can be temporally co-expressed within keratinocytes in vivo we wanted to assess if they fully intermixed within a gap junction plaque or whether they partitioned into separate regions of the same plaque. REKs expressing Cx30-GFP and immuno-labelled for Cx43 revealed that these connexins were localized to the same plaques ( Fig. 8A) , however, most of the Cx43 puncta were distinct from Cx30-GFP plaque regions ( Fig. 8B-D) . Next we used immuno-labelling to examine the localization pattern of Cx30 and Cx43 in NRKs (Fig. 8E ). High resolution z-stacks that were deconvolved into 3D images and rotated on a side angle revealed that Cx30 and Cx43 segregated into distinct, non-overlapping domains ( Fig. 8F-G) . In comparison, cells expressing both Cx30-GFP and Cx26-RFP had overlapping expression patterns ( Fig. 8H-K) , which is indicative of heteromeric or heterotypic gap junction configurations, as described previously (Marziano et al., 2003) .
DISCUSSION
Cx30 is a critical connexin in hearing and skin homeostasis. We and others have shown that loss-of-function Cx30 gene mutations can lead to severe deafness and devastating skin diseases or both (Berger et al., 2014; Bosen et al., 2014; Essenfelder et al., 2004; Grifa et al., 1999; Schutz et al., 2010; Wang et al., 2011 ). Yet, the cellular life cycle of this connexin remains poorly studied. Insights into its normal life-cycle may help determine how it serves essential roles in both hearing and epidermal function. In this study we provide compelling evidence in multiple cell types, including keratinocytes, that Cx30 exhibits a prolonged life in gap junctions (half-life >12 hrs) where it acts to maintain a stable level of GJIC. Thus, Cx30 is a novel connexin deviating from the short half-life of most other connexins (half-life 1-5 hrs)
that are expressed in cells that actively progress through the cell cycle (Beardslee et al., 1998; Darrow et al., 1995; Fallon and Goodenough, 1981; Laing et al., 1997; Laird et al., 1995; Laird et al., 1991; Thomas et al., 2005; Traub et al., 1989) . Our studies suggest that Cx30 may acquire a prolonged half-life compared to Cx43 by segregating into distinct subdomains within gap junction plaques although it can fully intermix with the highly homologous Cx26. Like many,
if not all connexins studied to date, Cx30 follows the classical secretory pathway by trafficking in a COPII-dependent manner through the Golgi apparatus. Distinct from Cx43, we also show that the stability of Cx30 gap junction plaques are not affected by cytoskeletal-disrupting drugs, whereas other aspects of the life cycle, such as gap junction renewal and internalisation via connexosomes, appear similar to other connexins.
Cx30 dynamics were assessed using time-lapse imaging of live cells expressing Cx30-GFP in connexin-deficient HeLa cells. We have previously shown that the presence of GFP does not affect the ability for Cx30 to traffic to the cell surface and form functional gap junction channels and hemichannels (Berger et al., 2014) . While a few Cx30 plaques were dynamic, splitting up and re-joining together again on numerous occasions, most plaques were immobile and stable at the cell surface. This could, however, be due to the presence of a EGFP tag at the C-terminus that may reduce Cx30 fluidity in the plasma membrane (Stout et al., 2015) . In some instances, such as when cells were migrating or dividing, whole Cx30-GFP plaques were internalized into connexosome-like structures, as has been reported for gap junction endocytosis previously (Gaietta et al., 2002; Jordan et al., 2001; Leithe et al., 2012; Piehl et al., 2007) . Interestingly, connexosomes appeared to separate into two groups: ones that were rapidly internalized and likely degraded and others that remained in close proximity to the cellcell border throughout the duration of the movie (~2 hrs). FRAP experiments revealed that, similar to Cx43 gap junctions (Falk et al., 2009; Gaietta et al., 2002; Lauf et al., 2002) , Cx30 gap junction plaques were replenished from the outer edge as older channels remained sequestered to the inner aspects of the plaques. Together, live cell examination of Cx30 gap junctions revealed that they are slow to turnover but when they do, they appear to follow the well-studied connexosome internalization pathway denoted by Cx43 (Gaietta et al., 2002; Jordan et al., 2001; Leithe et al., 2012; Piehl et al., 2007) . Furthermore, Cx30 gap junction plaque replenishment at the cell surface appears to be identical to Cx43 gap junctions (Gaietta et al., 2002; Lauf et al., 2002) in that new channels are sequestered to the outer edges of the plaques while older channels form the core of the plaque.
A report by Qu and colleagues (Qu et al., 2009) suggested that Cx30 could traffic to the cell surface via a Golgi independent pathway in HeLa cells. This was also previously suggested for Cx26 in HeLa and COS-7 cells (Martin et al., 2001 ), however we found that this was not the case for Cx26 in rat mammary tumour (BICR-M1Rk) or NRK cell lines (Thomas et al. 2005 ). In the present study, we concluded that Cx30 was routed through the classical secretory pathway in multiple cell types including keratinocytes based on its; 1) accumulation in a merged ER-Golgi compartment upon long-term treatment with BFA, 2) co-localization with resident markers of the ER in long-term BFA-treated cells and 3) accumulation in the ER compartment upon disruption of the Sar1-dependent protein transport pathway. Sar1 is a small
GTPase that recruits components of the coat protein complex II (COPII) to the ER membrane in its active GTP-bound form, whereas the mutant Sar1 H79G used in this study is unable to hydrolyse GTP to GDP and thus prevents Cx30 cargo-carrying vesicles from being transported to the Golgi apparatus. These data support a role for COPII-mediated transport of Cx30 vesicles along the secretory pathway. Thus, whether Cx30 is expressed in reference cell types such as HeLa or NRK cells or expressed in physiologically relevant keratinocytes, it is routed through the Golgi apparatus to the cell surface. Trafficking of Cx30 to or from the cell surface or the stability of pre-existing Cx30 gap junction plaques appeared unaffected by disrupting the microfilament or microtubule cytoskeletons. As previously demonstrated (Thomas et al., 2005) and shown here, Cx43 trafficking and plaque status is dramatically affected by the loss of microtubule integrity, whereas Cx26 trafficking is not dependent on intact microtubule networks. These data suggest that Cx43 assembly is more dependent on microtubules than either Cx26 (Thomas et al., 2001; Thomas et al., 2005) or Cx30. This may not be unexpected as the known tubulin binding site in the C-terminal tail of Cx43 (Giepmans et al., 2001a; Giepmans et al., 2001b ) is lacking in both Cx26 and Cx30.
Once assembled into a gap junction, we found that Cx30 has an unexpected long halflife (>12 hrs) when directly compared to Cx43 which has been well documented to have a short half of 1-5 hours in vitro (Darrow et al., 1995; Laing et al., 1997; Laird et al., 1995; Laird et al., 1991) and in vivo (Beardslee et al., 1998; Fallon and Goodenough, 1981) . Several comparative experiments with cells expressing or co-expressing both Cx43 and Cx30
suggested it was the fully assembled Cx30 gap junction plaques that were long lived as opposed to a possible population of Cx30 hemichannels. First, Cx30 expressing cells retained high levels of GJIC even after prolonged BFA treatment. Second, Cx30 gap junction localization was relatively unaffected by even long BFA treatment times. Third, Cx30 remained in a Triton X-100 insoluble pool after BFA treatment. Finally, total Cx30 clearing from the cell surface was highly delayed when cells were treated with the protein synthesis inhibitor, cycloheximide.
These results indicate that Cx30 has unique long-lived properties at the cell surface. This property was previously thought to be restricted to lens gap junctions consisting of mammalian Finally, our studies revealed that Cx30 was arranged into distinct sub-domains within plaques co-expressing Cx43, whereas Cx30 and Cx26 fully intermixed. Similar findings have been shown for Cx26 and Cx43 (Falk, 2000) and more recently with Cx30 and Cx43 (Stout et al., 2015) . However, Stout and colleagues went on to suggest that Cx30 and Cx43 segregation is attributed to using non-monomeric GFP tags at the C-terminus of Cx30. When a monomeric variant of GFP was used Cx30 and Cx43 no longer segregate into distinct domains (Stout et al., 2015) suggesting that tag was governing the connexin segregation. However, we found that untagged Cx43 and Cx30 segregate from each other in NRK cells expressing both connexins suggesting that, at least in some cells, they may retain innate properties to segregate that are independent of issues related to tagging. These findings are in agreement with previous reports that alpha (e.g. Cx43) and beta (e.g. Cx26 and now Cx30) connexins fail to intermix within gap junction channels (Gemel et al., 2004) , whereas Cx26 and Cx30 have been shown to form intermixed heteromeric gap junctions (Forge et al., 2003b; Yum et al., 2007) . In conclusion, this is the first study to demonstrate that Cx30 exhibits an unusually long half-life at the cell surface and that disruption of either the actin or tubulin cytoskeletal networks does not affect Cx30 gap junction stability. Interestingly, the main tissue-specific cell types that express large amounts of Cx30, namely the keratinocytes and inner ear supporting cells, are either terminally differentiated or quiescent and are often found in avascular tissue regions. These findings suggest that long-lived Cx30 gap junctions between cells that have exited the cell cycle and have reduced metabolism rates are important to; i) maintain adequate levels of GJIC, ii) conserve energy by reducing the need to constantly replenish gap junction plaques and iii) promote cell-cell adhesion, which may ultimately control processes such as migration during wound healing. These unique features may explain why mutations in the Cx30 gene (GJB6) are so detrimental to normal physiology.
MATERIALS AND METHODS
Generation of cDNA constructs
To create stable Cx26, Cx30 and Cx43 expressing HeLa cells: the rat Cx26 pCR3 construct was a gift from Dr. W. H. Evans and Dr. P. Martin (University of Wales College of Medicine, UK; (Martin et al., 1999) and mouse Cx30 pCR3 construct generated as described previously (Marziano et al., 2003) . All other experiments used the following DNA constructs:
mouse Cx30 encoded within the pBluescript vector was kindly provided by Dr. C. Naus (University of British Colombia, BC). To create a GFP-tagged construct, Cx30 cDNA was subcloned into a pEGFP-N1 (Clontech) expression vector, as described previously (Berger et al., 2014) . Sar1 and Sar1 H79G cDNA were cloned into pDsRed2-N1 (Clontech) vectors as described previously (Thomas et al., 2005) .
Cell culture, transfections and generation of stable cell lines
All media and reagents were obtained from Invitrogen/Life Technologies unless stated otherwise. Rat epidermal keratinocytes (REKs) were kindly provided by Vincent C. Hascall were split 48 hrs after transfection into several 10 cm culture dishes containing DMEM and 500 µg/ml of the selection antibiotic Geneticin (G418). After seven days, the concentration of G418 was reduced to 250 µg/ml to prevent cytotoxic effects. Individual cell colonies with a diameter of 2-3 mm were harvested using trypsin-soaked sterile cloning discs (3 mm, SigmaAldrich) and transferred to a 24-well plate. Clonal cells were plated onto coverslips between harvesting, fixed and checked for connexin expression using immunofluorescent labelling, as described later.
NRK cells were engineered to stably express mouse Cx30 by retroviral infection using the replication-defective AP2 vector (Galipeau et al., 1999) as described previously (Mao et al., 2000; Qin et al., 2002; Thomas et al., 2004) . Briefly, the AP-2 vector containing Cx30 cDNA was transfected into the 293GPG packaging cell line. Supernatants containing retroviral particles were collected, filter sterilized through a 0.45-μm filter (Pall Gelman Laboratories) and added to the NRK cells. After three rounds of infection, the cells were passaged and single cell colonies were selected. Clones with 100% Cx30 expression were selected for further experimentation.
Drug treatments
To block ER-to-Golgi transport, connexin-expressing cells were treated with 5 µg/ml brefeldin-A (BFA; Sigma-Aldrich) for up to 18 hrs in DMEM complete media at 37°C. To examine the relative half-life of Cx30, REKs were treated with 10 µg/ml of the translational inhibitor cycloheximide (CHX, Sigma-Aldrich). To elucidate the role of cytoskeletal elements in the stabilization of connexin plaques, Cx30 and Cx43 expressing REKs were treated with the microtubule disrupting drug nocodazole (10 μM; Sigma-Aldrich) or with the actin depolymerisation drug cytochalasin B (2.5 µg/ml; Sigma-Aldrich) for up to 10 hrs in DMEM complete media at 37 °C.
Live cell time-lapse imaging and fluorescence recovery after photobleaching (FRAP)
Cells expressing Cx30-GFP were plated into 35 mm glass-bottomed dishes (MatTek).
The dishes were mounted on a Zeiss 510 confocal microscope fitted with a temperature (37 o C) and CO2 (5%) control unit. Optical sections at a single z-plane or in z-stack were acquired every 20-30 seconds for up to 2 hrs using a 63x oil immersion lens (numerical aperture 1.4). Cx30-GFP was excited using a 488 nm argon laser and emitted fluorescence was collected after passage through a 500-550 nm band pass filter. In some cases, fluorescent images were simultaneously acquired and superimposed over a DIC image. FRAP was performed on specific Cx30-GFP gap junctions as described previously (Simek et al., 2009; Thomas et al., 2005) . Briefly, using ZEN 2011 (Zeiss) software a region of interest (ROI) was drawn around the plaque to be bleached. After acquiring 5-10 images at 20-30 sec intervals, the 'Edit Bleach' function was programmed to bleach the ROI using 30-60 iterations of the 488 laser at 100% emission intensity. Recovery of GFP fluorescence was then recorded using the 'Time Series' function by continuously acquiring single z-plane or z-stack images every 20-30 secs for up to recordings were reconstructed from the z-stack images using the ZEN 2011 3D software tool and exported as still images. The 3D time-lapse movies were created using Imaris 7.0 (Bitplane).
Immunofluorescent labelling
Cells expressing Cx30 or Cx43 were fixed with 10% neutral buffered formalin, permeabilized and blocked with 0.1% Triton X-100 (Sigma) and 3% bovine serum albumin 
Whole-cell tracer diffusion assay
To assess the extent of gap junctional coupling between stably expressing Cx26, Cx30
or Cx43 HeLa cells after BFA treatment, a whole-cell neurobiotin tracer study was performed as described previously (Kelly et al., 2011) . Briefly, HeLa cells grown on glass coverslips were pre-treated with BFA for 7 hrs or 0.01% (v/v) ethanol as a control. Coverslips were placed in a recording chamber on an upright microscope (Axioskop; Zeiss) and superfused with artificial extracellular solution (in mM: 145 NaCl, 4 KCl, 2 MgCl2, 1.3 CaCl2, and 5 glucose, pH adjusted to 7.3 with NaOH). Patch pipettes were filled with a potassium chloride intracellular solution (in mM: 140 KCl, 10 NaCl, 2 MgCl2, 5 HEPES, 5 EGTA, and 5 glucose, pH adjusted to 7.3 with KOH) supplemented with 1 mg/ml neurobiotin (MW, 287 Da; charge +1, Vector Laboratories). Once a giga-seal was formed suction was applied to create the whole-cell configuration and to allow neurobiotin to permeate into the cell. After 10 minutes the pipette was gently removed to form a tight seal. Cells were then fixed in 4% paraformaldehyde for 30 mins, permeabilized and blocked in 0.1% Triton X-100 and 0.1 mol/L l-lysine for 30 mins, before incubation for 2 hrs with Alexa Fluor 555-conjugated streptavidin (1:1000; Invitrogen, Cat #S-32355). Images were acquired on a Zeiss LSM 510 confocal microscope (Carl Zeiss).
All image settings were kept constant between coverslips. ImageJ software was used to count cells with neurobiotin present in the cytoplasm and nucleus. Data was collated, presented as mean ± s.e.m. and statistically analysed using the Student's t-test in GraphPad Prism4.
Western blotting
Cx30 and Cx43 expressing REK protein lysates were collected with a 1% Triton X-100 lysis buffer, as described previously (Penuela et al., 2007) . Protein concentrations were measured using a BCA protein determination kit (Pierce). In total, 20-30 μg of protein was resolved using 10% SDS-PAGE and transferred to a nitrocellulose membrane using the iBlot Dry Blotting System (Invitrogen). Membranes were blocked with 3% BSA-PBS containing 0.01% Tween and probed with rabbit polyclonal anti-Cx30 (0.25 µg/ml, Invitrogen, Cat #71-2200), rabbit polyclonal anti-Cx43 (0.55 µg/ml, Sigma-Aldrich, Cat #C6219) and mouse monoclonal GAPDH (0.1 µg/ml, Millipore, Cat #MAB374). Primary antibodies were detected using the fluorescently conjugated secondary antibodies goat anti-rabbit IRdye 800 (1:10000 dilution, LI-COR Biosciences) and Alexa Fluor 680 goat anti-mouse (1:10000 dilution, Invitrogen, A21057). Membranes were scanned and quantified using the Odyssey Infrared
Imaging System (LI-COR Biosciences). For CHX experiments, band intensities, normalized to the 0 hr time-point, were collated and a one-way ANOVA was performed on the averages of 3 biological replicates. Densitometry units are displayed ± s.e.m.
Triton solubility assay
Cx30 and Cx43 expressing REKs grown in 60mm dishes were pre-treated with BFA for 7 hrs, washed with cold PBS and Triton solubility assessed as described previously (Langlois et al., 2008) , with modifications. Briefly, cells were gently collected with a rubber policeman into 1 ml of cold PBS and spun down to a pellet. Cells were gently resuspended in 300 µl Triton lysis buffer containing 1% Triton X-100 plus 5 mM Tris-HCl (pH8.0), 2 mM EDTA, 2 mM EGTA, 1 mM NaF, 1 mM Na3VO4 and protease inhibitor (Roche). Cells were left for 30 mins on ice before pelleting and collecting the Triton-soluble supernatant. The remaining Triton-insoluble material was then dissolved in lysis buffer containing 1% SDS with sonication. Equal volumes of Triton X-100 soluble and insoluble fractions were separated by SDS-PAGE and subjected to Western blotting. GAPDH was used to verify the quality of the isolated fractions. Densitometry data is presented as mean ± s.e.m. and statistically analysed using the Student's t-test in GraphPad Prism4.
Figures Figure 1
Live-cell time lapse imaging of HeLa cells engineered to express Cx30-GFP. Gap junction plaques were clearly visible between cells at the 0 hr time-point (arrows). Images were acquired every 20 secs and plaques labelled 1, 2 and 3 were photobleached immediately after the 0 hr time-point. There was partial fluorescent recovery of the photobleached plaques as evident in the ovals labelled 1 and 3. A gap junction being internalized and degraded after cell-cell separation is denoted by the filled arrow whereas a connexosome that remained close to the initial junction region and was not degraded during the movie timeframe is denoted by a double arrow. Bars = 10 µm. 
